Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Status of clinical research in neurology in Germany-A national survey.
Lohmann L, Lammerskitten A, Korsen M, Dodel R, Gaul C, Hamer HM, Kleineberg NN, Ludolph AC, Mayer G, Poli S, Saur D, Steinhoff BJ, Timmermann L, Klotz L, Meuth SG. Lohmann L, et al. Among authors: korsen m. Eur J Neurol. 2021 May;28(5):1446-1452. doi: 10.1111/ene.14763. Epub 2021 Feb 26. Eur J Neurol. 2021. PMID: 33539600
Pain, depression, and quality of life in adults with MOG-antibody-associated disease.
Asseyer S, Henke E, Trebst C, Hümmert MW, Wildemann B, Jarius S, Ringelstein M, Aktas O, Pawlitzki M, Korsen M, Klotz L, Siebert N, Ruprecht K, Bellmann-Strobl J, Wernecke KD, Häußler V, Havla J, Gahlen A, Gold R, Paul F, Kleiter I, Ayzenberg I; Neuromyelitis Optica Study Group. Asseyer S, et al. Among authors: korsen m. Eur J Neurol. 2021 May;28(5):1645-1658. doi: 10.1111/ene.14729. Epub 2021 Feb 11. Eur J Neurol. 2021. PMID: 33423336
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
Rolfes L, Pfeuffer S, Hackert J, Pawlitzki M, Ruck T, Sondermann W, Korsen M, Wiendl H, Meuth SG, Kleinschnitz C, Pul R. Rolfes L, et al. Among authors: korsen m. Neurol Neuroimmunol Neuroinflamm. 2021 Apr 9;8(3):e990. doi: 10.1212/NXI.0000000000000990. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33837059 Free PMC article.
A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab.
Räuber S, Pawlitzki M, Korsen M, Kullmann JS, Thoene D, Pfeuffer S, Rolfes L, Nelke C, Melzer N, Ruck T, Meuth SG; INFUSE-MS study group. Räuber S, et al. Among authors: korsen m. Mult Scler Relat Disord. 2022 Mar;59:103670. doi: 10.1016/j.msard.2022.103670. Epub 2022 Feb 5. Mult Scler Relat Disord. 2022. PMID: 35150978 Free article.
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
Räuber S, Korsen M, Huntemann N, Rolfes L, Müntefering T, Dobelmann V, Hermann AM, Kölsche T, von Wnuck Lipinski K, Schroeter CB, Nelke C, Regner-Nelke L, Ingwersen J, Pawlitzki M, Teegen B, Barnett MH, Hartung HP, Aktas O, Albrecht P, Levkau B, Melzer N, Ruck T, Meuth SG, Kremer D. Räuber S, et al. Among authors: korsen m. J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):978-985. doi: 10.1136/jnnp-2021-328197. Epub 2022 Feb 22. J Neurol Neurosurg Psychiatry. 2022. PMID: 35193952 Free PMC article.
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
Pfeuffer S, Rolfes L, Ingwersen J, Pul R, Kleinschnitz K, Korsen M, Räuber S, Ruck T, Schieferdecker S, Willison AG, Aktas O, Kleinschnitz C, Hartung HP, Kappos L, Meuth SG. Pfeuffer S, et al. Among authors: korsen m. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 11;10(3):e200104. doi: 10.1212/NXI.0000000000200104. Print 2023 May. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37041077 Free PMC article.
21 results